AnaptysBio (ANAB) Gains From Jemperli Approval, Is The Royalty Upside Already Priced In?
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
AnaptysBio (ANAB) is gaining attention following the U.S. FDA approval of GSK’s Jemperli for locally advanced rectal cancer, as AnaptysBio licenses the antibody and benefits economically from its success. Despite a recent slight dip, ANAB's share price shows strong long-term momentum with a 3-year total shareholder return of 343.7%.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.